Efficacy of a Daltuzumab-containing Regimen in Patients with mSMART High-Risk Multiple Myeloma
10.19746/j.cnki.issn1009-2137.2024.03.018
- VernacularTitle:含达雷妥尤单抗的方案治疗mSMART高危多发性骨髓瘤患者的疗效观察
- Author:
Zhen-Lun QI
1
;
Ya-Qin LUO
;
Shu-Min DING
;
Zhao-Xia LIU
Author Information
1. 山东中医药大学
- Keywords:
daratumumab;
multiple myeloma;
efficacy;
safety
- From:
Journal of Experimental Hematology
2024;32(3):774-779
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of a treatment regimen based on daratumumab in patients with high-risk relapsed refractory multiple myeloma(MM)with mSMART 3.0 score.Methods:Clinical data were collected from 16 patients with mSMART3.0 score high-risk relapsed refractory MM treated at the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from May 2020 to May 2023,all of whom received daltezumab-based regimen(regimen drugs including dexamethasone,isazomib,bortezomib,lenalidomide).The efficacy and safety of the treatment were retrospectively analyzed.Results:The median age of 16 patients was 63.5(47-70)years old,including 10 cases of IgG type,2 cases of IgA type,and 4 cases of light chain type.The curative efficacy was judged in all 16 patients,with an overall response rate of 93.75％(15/16),including 4 cases of strict complete remission(sCR),1 case of complete remission(CR),2 case of very good partial remission(VGPR),partial remission(PR)in 5 cases,and minor remission(MR)in 3 cases.The median follow-up time was 11(2-30)months,and the median progression-free survival and median overall survival were not achieved in 16 patients at the median follow-up period.The hematologic adverse effects of the treatment regimen using daratumumab-based were mainly neutropenia,and the non-hematologic adverse effects were mainly infusion-related adverse reactions and infections.Conclusion:Daratumumab-based regimen for the treatment of relapsed refractory MM patients with high risk of mSMART3.0 score has better efficacy and safety.
